/ Not yet recruitingNot Applicable Safety, Performance and Lesion Evaluation of Neurothrombectomy Using CEREGLIDE 92 Intermediate Catheter: A Prospective Multi-Center Single-Arm IDE Trial (SPLENDID)
The device is indicated for use in the revascularization of patients with acute ischemic stroke secondary to intracranial large vessel occlusive disease
/ Not yet recruitingNot Applicable Feasibility Study to Evaluate the Initial Safety and Effectiveness of TRUFILL n-BCA Liquid Embolic System in Middle Meningeal Artery Embolization for the Preventive Treatment of Refractory Chronic Migraine
This is a prospective, multi-center, feasibility study to investigate safety and effectiveness of TRUFILL n-BCA liquid embolic system in bilateral middle meningeal artery (MMA) embolization for the treatment of refractory chronic migraine.
/ Active, not recruitingNot Applicable Middle Meningeal Artery Embolization for the Treatment of Subdural Hematomas With TRUFILL® n-BCA
This is a prospective, multi-center, open-label, randomized controlled study in which subjects can receive standard of care (SOC) alone or SOC and TRUFILL n-BCA MMA embolization for the treatment of chronic subdural hematomas (cSDH).
100 Clinical Results associated with Cerenovus, Part of DePuy Synthes Products, Inc.
0 Patents (Medical) associated with Cerenovus, Part of DePuy Synthes Products, Inc.
100 Deals associated with Cerenovus, Part of DePuy Synthes Products, Inc.
100 Translational Medicine associated with Cerenovus, Part of DePuy Synthes Products, Inc.